Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.

Engel AR, Rumyantsev AA, Maximova OA, Speicher JM, Heiss B, Murphy BR, Pletnev AG.

Virology. 2010 Sep 15;405(1):243-52. doi: 10.1016/j.virol.2010.06.014. Epub 2010 Jul 1.

2.

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG.

Vaccine. 2006 Jan 12;24(2):133-43. Epub 2005 Aug 9.

PMID:
16115704
3.

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Pletnev AG, Bray M, Huggins J, Lai CJ.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10532-6.

4.
5.

Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes.

Engel AR, Mitzel DN, Hanson CT, Wolfinbarger JB, Bloom ME, Pletnev AG.

Vector Borne Zoonotic Dis. 2011 Jun;11(6):665-74. doi: 10.1089/vbz.2010.0179. Epub 2010 Dec 13.

8.

Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype.

Heiss BL, Maximova OA, Pletnev AG.

J Virol. 2011 Feb;85(4):1464-72. doi: 10.1128/JVI.02091-10. Epub 2010 Dec 1.

9.
10.

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Blaney JE Jr, Speicher J, Hanson CT, Sathe NS, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Aug 5;26(33):4150-9. doi: 10.1016/j.vaccine.2008.05.075. Epub 2008 Jun 13.

11.

Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.

Pripuzova NS, Tereshkina NV, Gmyl LV, Dzhivanyan TI, Rumyantsev AA, Romanova LIu, Mustafina AN, Lashkevich VA, Karganova GG.

J Med Virol. 2009 Oct;81(10):1777-85. doi: 10.1002/jmv.21587.

PMID:
19697399
12.
13.

[Residual neurovirulence of the chimera of Langat and Denge-4 flaviviruses in intracerebral infection of monkeys].

Karganova GG, Pripuzova NS, Tereshkina NV, Gmyl' LV, Dzhivanian TI, Rumiantsev AA, Lashkevich VA.

Vopr Virusol. 2005 Jan-Feb;50(1):27-31. Russian.

PMID:
15747868
14.

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Feb 13;26(7):882-90. doi: 10.1016/j.vaccine.2007.12.015. Epub 2008 Jan 4.

15.

MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives.

Teterina NL, Maximova OA, Kenney H, Liu G, Pletnev AG.

Antiviral Res. 2016 Mar;127:57-67. doi: 10.1016/j.antiviral.2016.01.003. Epub 2016 Jan 19.

16.
17.

Isolation and molecular characterization of a tick-borne encephalitis virus strain from a new tick-borne encephalitis focus with severe cases in Bavaria, Germany.

Kupča AM, Essbauer S, Zoeller G, de Mendonça PG, Brey R, Rinder M, Pfister K, Spiegel M, Doerrbecker B, Pfeffer M, Dobler G.

Ticks Tick Borne Dis. 2010 Mar;1(1):44-51. doi: 10.1016/j.ttbdis.2009.11.002. Epub 2010 Jan 7.

PMID:
21771510
18.

A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Guirakhoo F, Zhang Z, Myers G, Johnson BW, Pugachev K, Nichols R, Brown N, Levenbook I, Draper K, Cyrek S, Lang J, Fournier C, Barrere B, Delagrave S, Monath TP.

J Virol. 2004 Sep;78(18):9998-10008.

19.

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus.

Pletnev AG, Karganova GG, Dzhivanyan TI, Lashkevich VA, Bray M.

Virology. 2000 Aug 15;274(1):26-31.

20.

Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.

Blaney JE Jr, Manipon GG, Firestone CY, Johnson DH, Hanson CT, Murphy BR, Whitehead SS.

Vaccine. 2003 Oct 1;21(27-30):4317-27.

PMID:
14505914

Supplemental Content

Support Center